PXS-5505 + atezolizumab + bevacizumab

PXS-5505 + atezolizumab + bevacizumab is an investigational combination therapy comprising three agents with distinct mechanisms of action. PXS-5505 is a first-in-class, orally bioavailable, small molecule inhibitor that irreversibly targets all members of the lysyl oxidase (LOX) enzyme family, including LOX and LOXL1–4. By inhibiting these enzymes, PXS-5505 disrupts collagen and elastin cross-linking in the extracellular matrix, reducing fibrosis and tumor stiffness. This can enhance drug penetration into tumors and potentially improve antitumor immune responses[1][3][4][6]. Atezolizumab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to restore T-cell mediated antitumor immunity. Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis within tumors. The combination aims to simultaneously remodel the tumor microenvironment by reducing fibrosis (via PXS-5505), enhance immune-mediated tumor cell killing (via atezolizumab), and inhibit new blood vessel formation required for tumor growth (via bevacizumab). This multi-pronged approach may be particularly relevant in desmoplastic or fibrotic solid tumors such as pancreatic cancer or cholangiocarcinoma[3][6].